Company* (Country; Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)

AC Immune Ltd.* (Switzerland)

Genentech Inc. (NYSE:DNA)

Deal to develop anti-beta-amyloid antibodies for treating Alzheimer's disease and other conditions

AC Immune gets up-front and research funding; it could get more than $300M in milestones for Alzheimer's and additional indications, and would get royalties on resulting sales (12/7)

Advanced In Vitro Cell Technologies Inc.* (Spain)

Protherics plc (UK; LSE:PTI)

Protherics got rights to Acadesine, which is being developed for B-cell chronic lymphocytic leukemia

A proof-of-concept Phase I/II trial is planned for 2007; terms of the license and co-development deal were not disclosed (12/8)

Adventrx Pharmaceuticals Inc. (AMEX:ANX)

Theragenex LLC*

Theragenex got U.S. rights to ANX-211, an intranasal/topical antiviral agent

Adventrx gets $1M up front and would get $1M for each resulting product launch; it also would get royalties of 15 to 20 (10/23)

Amarillo Biosciences Inc. (OTC BB:AMAR)

CytoPharm Inc. (unit of Vita Genomics Inc.; Taiwan)

CytoPharm gained rights in China and Taiwan to ABI's low-dose oral interferon

CytoPharm will conduct trials of the product for treating influenza and hepatitis B; ABI is eligible to receive milestone and royalty payments in the deal (11/27)

Ambit Biosciences Corp.*

Cephalon Inc. (CEPH)

Ambit will use its screening technology in a collaboration to discover and develop kinase inhibitors

Ambit gets $18M up front and up to $232.5M in milestone payments, as well as royalties on resulting sales (11/6)

Archemix Corp.*

Ribomic Inc.*

Ribomic got nonexclusive rights to an IgG aptamer for affinity purification uses

Archemix gets an up-front payment, and is eligible to receive milestone payments and royalties on resulting sales (11/29)

Bioject Medical Technologies Inc. (BJCT)

Vical Inc. (VICL)

Vical got an option to license needle-free delivery technology for use with certain DNA-based vaccines

Bioject is entitled to an up-front payment, payments to extend the option term and license additional targets, milestone payments, transfer fees and royalties on resulting sales (11/7)

Caprion Pharmaceuticals Inc.*

Vertex Pharmaceuticals Inc. (VRTX)

They expanded deal from March under which Caprion is supporting biomarker discovery at Vertex

They will continue to apply Caprion's CellCarta proteomics technology across preclinical and clinical development at Vertex; terms were not disclosed (10/25)

CellSeed Inc.* (Japan)

ReNeuron Group plc (UK; LSE:RENE)

Deal to develop liver cell culture systems for drug safety screening

The effort will combine ReNeuron's HEP hepatocyte cell lines with CellSeed's polymer products; terms were not disclosed (11/30)

China Biopharma Inc. (OTC BB:CBPC)

HYTE Research LLC*

Deal to develop and market Nano-Poly enhancement vaccine technology

China Biopharma will hold 55 of resulting intellectual property rights; the goal is to develop technology to improve the safety and efficacy of human vaccines (11/29)

Cytokine PharmaSciences Inc.*

Genmab A/S (Denmark; CSE:GEN)

Genmab gained rights to the MIF receptor target

Genmab intends to develop human antibodies to the target; terms of the deal were not disclosed (11/20)

Dyax Corp. (DYAX)

ZymoGenetics Inc. (ZGEN)

ZymoGenetics got non-exclusive rights to antibody phage display libraries for discovery of therapeutic antibodies

Dyax gets up-front and annual technology license fees, and is eligible to receive milestone payments, as well as royalties on resulting sales (10/31)

EnBioTec Laboratories Co. Ltd. (Japan)

Tripos Inc. (TRPS)

Deal to co-develop nuclear receptor-based lead compounds for drug discovery

EnBioTec will work with Tripos Discovery Research Ltd. in the UK in the effort; terms of the deal were not disclosed (11/1)

Endotherm GmbH* (Germany)

PharmaInformatic* (Germany)

Collaboration to develop and optimize antiviral agents

PharmaInformatic will evaluate properties of compounds, while Endotherm will identify and synthesize those with promise; terms were not disclosed (12/12)

Epidauros Biotechnologie AG* (Germany)

InPheno AG (Switzerland)

Deal to pool technologies in a sales and marketing partnership

They will offer services in the areas of genotyping and phenotyping; terms of the deal were not disclosed (11/30)

Glenveigh Pharmaceuticals LLC*

Protherics plc (UK; LSE:PTI)

Protherics got rights to use ovine polyclonal antibody fragments in treatments for pre-eclampsia and eclampsia

Terms of the deal were not disclosed (12/8)

Immunomic Therapeutics Inc.*

Geron Corp. (GERN)

Geron got exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines

The sequence will be used to enhance the immune response of a Geron vaccine; ITI had licensed the technology from Johns Hopkins University; terms of the deal were not disclosed (11/6)

Indevus Pharmaceuticals Inc. (IDEV)

Novexel SA* (France)

Novexel gained worldwide rights to aminocandin, an antifungal agent from the echinocandin class

Indevus originally got rights from Sanofi-Aventis Group, which later spun Novexel out; Indevus gets $1.5M up front, along with $43M in potential milestone payments and royalties on resulting sales (12/5)

Innate Pharma SA (France; Euronext:IPH)

Clinical Data Inc. (CLDA)

Clinical Data got rights to develop a pharmacogenetic test related to therapeutic antibodies for cancer

The test is based on variations in the Fc-gamma receptor gene; terms of the deal were not disclosed (11/9)

Inovio Biomedical Corp. (AMEX:INO)

VGX Pharmaceuticals Inc.*

VGX got nonexclusive rights to use DNA delivery technology for intratumoral delivery of a gene to control the growth of melanoma and other cancers

Inovio gets an up-front license fee and potential milestone payments; it will supply electroporation devices, and would get royalties on resulting sales (11/14)

Lay Line Genomics SpA* (Italy)

PanGenetics BV* (the Netherlands)

PanGenetics got rights to Hu-alphaD11, a humanized antibody against nerve growth factor that targets pain

Lay Line gets up-front and research payments, and could receive milestone and royalty payments; PanGenetics has development and commercialization responsibilities (12/7)

MD Biosciences* (Switzerland)

Medisyn Technologies Inc.*

Collaboration to discover small molecules targeting inflammatory and neurological diseases

Each company will contribute discovery platforms to the effort; lead compounds would be licensed out; commercialization rights will be shared equally (10/26)

Metabasis Therapeutics Inc. (IDIX)

Idenix Pharmaceuticals Inc. (MBRX)

Metabasis will apply its liver-targeting technology to Idenix compounds to develop second-generation nucleoside analogues for treating hepatitis C

Metabasis gets $2M up front, and Idenix will fund the work; for a lead compound, Metabasis would be eligible to receive up to $23.5M in development milestones, and $40M upon regulatory approval; it also would get royalties on sales (10/26)

Microbix Biosystems Inc. (Canada; TSX:MBX)

Angiogen LLC*

Deal for commercialization of a combination therapy for treating solid cancers

Microbix will provide urokinase for the program; further details were not disclosed (11/2)

PacMab Ltd.* (Australia)

Medarex Inc. (MEDX)

Collaboration to develop monoclonal antibody-based therapies for blood cancers

They plan to move a PacMab antibody into the clinic, and to generate new fully human antibodies against new targets; they will share development and commercialization responsibilities; terms were not disclosed (11/7)

Sareum Holdings plc (UK; AIM:SAR)

Genentech Inc. (NYSE:DNA)

Sareum will perform research services on multiple drug targets from Genentech

Sareum gets research fees and milestone payments of up to $1.5M in the one-year deal, which may be extended (11/20)

Scion Pharmaceuticals Inc.*

Xention Ltd.* (UK)

Xention acquired exclusive rights to certain ion channel modulators, which will be studied in various diseases

Xention also entered a deal with Bristol-Myers Squibb Co., which had licensed the compounds to Scion; that deal expanded the potential fields of development (12/4)

Targeted Genetics Corp. (TGEN)

Amsterdam Molecular Therapeutics BV (the Netherlands)

AMT got nonexclusive rights to use adeno-associated virus technology in products to treat types I and V lipoprotein lipase deficiencies

Targeted Genetics gets $1.75M up front and is eligible to receive milestone and royalty payments (12/12)

ThromboGenics NV (Belgium; Euronext:THR)

Bharat Biotech International Ltd.* (India)

Bharat got rights to the Phase II thrombolytic agent THR-100, a variant of recombinant staphylokinase

The deal covers developing countries and certain industrialized countries; Bharat will assume all costs; ThromboGenics would get double-digit royalties on resulting sales (12/7)

TMRC Co. Ltd.* (Japan)

Innovive Pharmaceuticals Inc. (OTC BB:IVPH)

Innovive got North American rights to tamibarotene, a synthetic retinoid for acute promyelocytic leukemia

The product is on the market in Japan; a pivotal study in the U.S. is planned for 2007; TMRC got an up-front fee, and is eligible to receive milestone and royalty payments (12/8)

Valentis Inc. (VLTS)

Vical Inc. (VICL)

Vical acquired pending patents that complement its technology in poloxamers and angiogenesis

Vical also got nonexclusive rights to technology directed toward manufacturing; terms of the deal were not disclosed (10/31)


* Private companies are indicated with an asterisk.

Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.